Back to all blog posts
Hi everyone,
To say 2021 marked some historic milestones for Aiforia Technologies Plc would be an understatement. Looking back on what we have achieved this past year, I am incredibly humbled and proud of the Aiforia team.
On December 10th at 10am Helsinki time Aiforia Technologies Plc began trading in our shares on Nasdaq First North Growth Market Finland. For the efforts leading up to the moment of ringing the bell at the Helsinki Stock Exchange to mark the company’s IPO, I would like to give an enormous thanks to the Aiforia team, our partners, investors, advisors, customers, shareholders and all the other brilliant individuals involved in this process.
Other key highlights of 2021 along the way to the IPO include:
- Closing our Series B Funding round of €17.5M: this year we announced the completion of the financing led by Epredia's UK entity, a subsidiary of PHC Holdings Corporation, with the intention of allocating the funds to accelerate the development and commercialization of Aiforia’s portfolio of clinical tools for AI-assisted support in the diagnosis of some of the world’s most prevalent diseases like breast and lung cancer.
- Two CE-IVD marked products: the Aiforia Clinical AI models: ki67 for breast cancer diagnostics and PD-L1 for lung cancer diagnostics recently received CE-IVD markings to support pathologists in the efficient review of patient samples to produce quick and reproducible data benefiting oncologists and patients alike.
- Agreement signed with a major US hospital network this year, one which the U.S. News & World Report¹ has once again recognized as the number one hospital overall in the United States. The agreement encompasses the sale of software solutions intended for both preclinical research and clinical diagnostics use by the hospital, which intends to bring numerous AI models to use in their diagnostic workflows during 2022 with the first such AI model being the model intended for diagnosing breast cancer through the quantification of the Ki67 biomarker. Furthermore for preclinical use the hospital intends to have Aiforia’s software, Aiforia Create, used by several dozen of its pathologists and scientists for the creation of new AI models.
- Partnership with Epredia for the global distribution of AI-powered pathology software. With Epredia, a global leader in precision cancer diagnostics, we believe they are the ideal commercial partner to help us broaden the international reach of Aiforia’s AI software.
- Receiving ISO 27001 certification, the premier global standard for Information Security Management Systems, is a major milestone for us in bringing further confidence to our customers in the safety and privacy of their data and showcasing our commitment to providing high quality tools.
Looking ahead to 2022 I believe with our growing team and growing number of powerful products and services we will continue to advance our international reach. Our business objectives include expanding our portfolio of CE-IVD marked AI models for clinical diagnostics as well as our number of users significantly in both preclinical and clinical pathology, and working towards creating a product offering covering the majority of the pathologist’s diagnosing workflow.
Aiforia aims to transform image-based diagnostics by escalating efficiency and precision beyond current capabilities. Our mission is to provide the highest quality solutions for AI-assisted image analysis to enable personalised and democratised care for patients. I truly believe this would not be possible without our employees; their commitment, talent and tenacity. Therefore I would like to thank you all for your dedication this year and look forward to another year of many successes shared together!
Happy holidays!
Best regards,
Jukka Tapaninen
CEO
Aiforia Technologies Plc
References
- https://health.usnews.com/best-hospitals